孕期COVID-19疫苗接种安全性与有效性的早期探索:前瞻性观察研究的 interim 描述性数据
本研究通过在线问卷前瞻性观察接种与未接种孕妇,比较短期妊娠结局。接种组与未接种组复合妊娠并发症发生率相似(15.8% vs 20.1%,p=0.37),接种组COVID-19感染风险显著更低(1.5% vs 6.5%,p=0.024,OR=4.5,95%CI 1.19-17.6)。结论认为孕期mRNA疫苗不增加妊娠并发症且有效预防感染。
要点
- 孕期接种mRNA疫苗未增加复合妊娠并发症风险。
- 接种组COVID-19感染率显著低于未接种组。
- 研究为在线问卷前瞻性观察,样本有限,需更多证据。
核心结论
- 孕期mRNA疫苗接种不增加妊娠并发症率,且有效预防COVID-19感染。
研究设计与样本
- 前瞻性观察性队列研究,通过Facebook和WhatsApp针对医疗群体的在线Google forms问卷招募接种与未接种孕妇,首次问卷后一个月发送第二次问卷进行 interim 分析。
- 首次问卷共432名女性应答,第二次问卷收到326份应答。
主要发现
- 一个月内疫苗接种率从25.5%升至62%。
- 接种组与未接种组复合妊娠并发症发生率相似(15.8% vs 20.1%,p=0.37)。
- 接种组COVID-19感染风险显著低于未接种组(1.5% vs 6.5%,p=0.024,OR=4.5,95%CI 1.19-17.6)。
- 两组在母亲年龄、入组时孕龄、未产比例及子女数量方面相似。
关键数值与推荐
- 主要结局为复合并发症:阴道出血、妊娠丢失、高血压、妊娠期糖尿病和早产。
- 次要结局包括疫苗副作用、自上次问卷以来COVID-19诊断、接种者比例及拒绝接种原因。
临床怎么用
- 可为孕期女性提供mRNA疫苗接种建议时参考,以降低COVID-19感染风险且不增加短期妊娠并发症。
- 需结合更多研究证据进行个体化咨询。
局限性
- 研究为在线问卷招募,可能存在选择偏倚。
- 样本量有限,interim 分析数据。
- 短期观察,未报告长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: During December 2020, a massive vaccination program was introduced in our country. The Pfizer-BioNTech, BNT162b2 vaccine was first offered exclusively to high-risk population, such as medical personnel (including pregnant women). In this study we compare short term outcomes in vaccinated vs. non-vaccinated pregnant women. METHODS: In this prospective observational cohort study, vaccinated and non-vaccinated pregnant women were recruited using an online Google forms questionnaire targeting medical groups on Facebook and WhatsApp. A second questionnaire was sent one month after the first one for interim analysis. Our primary outcome was composite complications in vaccinated and non-vaccinated groups, considered any of the following: vaginal bleeding, pregnancy loss, hypertension, gestational diabetes, and preterm birth. Secondary outcomes included: vaccine side effects, diagnosis of COVID-19 since the last questionnaire, prevalence of vaccinated participants, and reasons for refusal to be vaccinated. RESULTS: Overall, 432 women answered the first questionnaire, of which 326 responses were received to the second questionnaire. Vaccination rate increased from 25.5% to 62% within a month. Maternal age, gestational age at enrollment, nulliparity and number of children were similar in both groups. The rate of composite pregnancy complications was similar between vaccinated and non-vaccinated group (15.8% vs 20.1%, p = 0.37), respectively. The risk for COVID-19 infection was significantly lower in the vaccinated group (1.5% vs 6.5%, p = 0.024, Odds Ratio: 4.5, 95% confidence interval 1.19-17.6). CONCLUSIONS: mRNA vaccine during pregnancy does not seem to increase the rate of pregnancy complications and is effective in prevention of COVID-19 infection.
引用
- Bleicher I, Kadour-Peero E, Sagi-Dain L, et al. Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study. Vaccine. 2021. PMID: 34600749. doi:10.1016/j.vaccine.2021.09.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。